6533b7d4fe1ef96bd12631e6

RESEARCH PRODUCT

Modification of Interleukin-15 Serum Levels in Workers Exposed to Chemotherapeutic Agents

Giovanna SpatariElvira Ventura-spagnoloSebastiano GangemiGiuseppe Di PasqualeConcettina FengaPaola Lucia MinciulloCacciola A

subject

AdultMaleImmunologyAntineoplastic AgentsPharmacologyAntineoplastic AgentSettore MED/43 - Medicina LegaleIn vivoOccupational ExposureHealth carelcsh:PathologyMedical StaffmedicineHumansCarcinogenInterleukin-15business.industryCase-control studyCancerCell BiologyMiddle Agedmedicine.diseaseInterleukin 15Case-Control StudiesFemaleOccupational exposureTeratogenic riskCase-Control StudiebusinessRapid Communicationlcsh:RB1-214Human

description

Cytostatic anticancer drugs are known as carcinogenic, mutagenic, and teratogenic risk factors for health care workers occupationally exposed. It has been demonstrated that the administration of interleukin-15 in rat models of colon carcinoma protects against chemotherapy-induced gastrointestinal toxicities. We found that occupational exposure to chemotherapeutic antiblastic agents in vivo modified circulating levels of interleukin-15 in 17 health care workers exposed to antineoplastic drugs in relation to their jobs and in as many healthy age- and sex-matched subjects. Health care workers displayed significantly higher circulating interleukin-15 levels compared to their age-matched controls. If this increase representing an anticancer response remains to be established, these findings strengthen the idea of a therapeutic use of interleukin-15 in the field of cancer. © 2005 Hindawi Publishing Corporation.

yearjournalcountryeditionlanguage
2005-03-17Mediators of Inflammation
https://doi.org/10.1155/mi.2005.60